Seres Therapeutics, Inc. (MCRB) Operating income 2016–2025
Seres Therapeutics, Inc. (MCRB) annual operating income history from SEC filings — each fiscal year as reported.
-$94.0MFY2025 · since FY2016: -$92.8M → -$94.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$94.0M | +22.5% |
| FY2024 | -$121.3M | +37.8% |
| FY2023 | -$195.1M | -8.4% |
| FY2022 | -$179.9M | -179.0% |
| FY2021 | -$64.5M | +26.8% |
| FY2020 | -$88.1M | -22.6% |
| FY2019 | -$71.9M | +28.3% |
| FY2018 | -$100.3M | -9.7% |
| FY2017 | -$91.4M | +1.6% |
| FY2016 | -$92.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating marginMCRB Operating cash flowMCRB Free cash flowMCRB Capital expendituresMCRB Return on equityMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Total liabilitiesMCRB Shareholders’ equityMCRB overview →